Amarantus Bioscience February Update

As part of our ongoing efforts to introduce our readers to intriguing investment opportunities, OneMedPlace has published an update of Amarantus Bioscience (AMBS). In our February Report, we discuss major developments, including the release of promising data (announced at OneMedForumSF 2013 in January) for the company’s first-in-class curative therapy for Parkinson’s disease and the acquisition of a diagnostic platform for apoptosis-related medical conditions, including PD.

View the February Update here.

The comments are closed.